摘要：【中文】本发明涉及一种用于机动车的SCR催化系统的操纵识别的方法。在该方法中，由在机动车外的控制单元发送的、针对机动车的SCR催化系统的控制指令（61）被接收（51）。当SCR催化系统对实施（54）控制指令（61）的回应（55）不符合预期时，识别到（57）操纵。本发明还涉及一种用于对SCR催化系统进行操纵监控的方法。在此，用于SCR催化系统的控制指令（61）由机动车外的控制单元（20）发送（41）给机动车（10）。 【EN】The invention relates to a method for detecting an actuation of an SCR catalytic system of a motor vehicle. In the method, a control command (61) for an SCR catalytic system of a motor vehicle, which is sent by a control unit outside the motor vehicle, is received (51). When the response (55) of the SCR catalytic system to the execution (54) of the control command (61) is not expected, an actuation is detected (57). The invention also relates to a method for monitoring the operation of an SCR catalytic system. A control command (61) for the SCR catalytic system is sent (41) from a control unit (20) outside the motor vehicle to the motor vehicle (10).

摘要：【中文】描述了用于检测路径故障并且减少由于这种故障而导致的分组丢失的技术，以用于数据中心或其他环境中。例如，源和/或目的地接入节点可以创建和/或维护关于源设备和目的地设备与核心交换机之间的多个端口或路径的健康和/或连接性的信息。源接入节点可以在源接入节点与目的地接入节点之间的许多路径上喷射分组。源接入节点可以使用关于源接入节点或目的地接入节点与核心交换机之间的路径的连接性的信息以限制在其上喷射分组的路径。源接入节点可以在被标识为健康的源接入节点与目的地接入节点之间的路径上喷射分组，同时避开已经被标识为故障的路径。 【EN】Techniques for detecting path failures and reducing packet loss due to such failures are described for use in data centers or other environments. For example, the source and/or destination access nodes may create and/or maintain information regarding the health and/or connectivity of a plurality of ports or paths between the source and destination devices and the core switch. A source access node may inject packets on many paths between the source access node and a destination access node. The source access node may use information about the connectivity of the path between the source access node or the destination access node and the core switch to limit the path over which the packet is injected. The source access node may inject packets on paths between the source access node and the destination access node that are identified as healthy while avoiding paths that have been identified as failed.

摘要：【中文】一种用于注射模制药物载体的配制品包括43.5‑97％(w/w)的重均分子量为MW 94,000‑188,000的一种或多种聚环氧乙烷聚合物、以及可选地一种或多种赋形剂。 【EN】A formulation for injection molding a pharmaceutical carrier includes 43.5-97% (w/w) of one or more polyethylene oxide polymers having a weight average molecular weight MW 94,000-188,000, and optionally one or more excipients.

摘要：【中文】一种药物载体(20)包括盖部(22)和底部(24)，其中，所述盖部(22)和所述底部(24)中的至少一者具有厚度为180‑250μm、优选地185‑225μm、甚至更优选地190‑220μm、并且最优选地约215μm的第一壁区段(26，30)，以及厚度为350‑450μm、优选地375‑425μm、更优选地390‑410μm、并且最优选地约400μm的第二壁区段(28，32)。所述盖部(22)的第一壁区段(26)限定所述盖部(22)的整个顶部分。替代于或附加于此，所述底部(24)的第一壁区段(30)限定所述底部(24)的整个底部分。 【EN】A drug carrier (20) comprising a lid portion (22) and a bottom portion (24), wherein at least one of the lid portion (22) and the bottom portion (24) has a first wall section (26, 30) with a thickness of 180-. The first wall section (26) of the cover (22) defines the entire top portion of the cover (22). Alternatively or additionally thereto, the first wall section (30) of the bottom (24) defines the entire bottom portion of the bottom (24).